Brought to you by 
Elan, UCB Pharma co-promote Frova in the US
24 Aug 2004
Executive Summary
UCB Pharma (neurological diseases and asthma/allergies) will co-promote Elan Corp.'s migraine drug Frova (frovatriptan succinate) in the US over a seven-year period.
Deal Industry
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Elan, UCB Pharma co-promote Frova in the US
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice